Literature DB >> 22228749

Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.

Jialin Mao1, Michael A Mohutsky, John P Harrelson, Steven A Wrighton, Stephen D Hall.   

Abstract

Cryopreserved human hepatocytes suspended in human plasma (HHSHP) have previously provided accurate CYP3A drug-drug interaction (DDI) predictions from a single IC(50) that captures both reversible and time-dependent inhibition. The goal of this study was to compare the accuracy of DDI predictions by a protein-free human hepatocyte system combined with the fraction unbound in plasma for inhibitor(s) with those obtained with protein-containing incubations. Seventeen CYP3A, CYP2C9, or CYP2D6 inhibitors were incubated with hepatocytes in human plasma or hepatocyte maintenance medium (HMM) for 20 min over a range of concentrations after which midazolam 1'-hydroxylation, diclofenac 4'-hydroxylation or (R)-bufuralol 1'-hydroxylation were used to quantify the corresponding cytochrome P450 (P450) catalytic activities. Two methods were used to predict the human exposure ratio of the victim drug in the presence and absence of inhibitor. The HMM K(i, app) values were combined with the free average systemic plasma concentration ("free [I] with HMM K(i, app)") and the plasma K(i, app) values were combined with the total average systemic plasma concentration ("total [I] with plasma K(i, app)"). Of 63 clinical DDI studies, the total [I] with plasma K(i, app) method predicted 89% of cases within 2-fold of the reported interaction whereas the free [I] with HMM K(i, app) method predicted only 59%. There was a general underprediction by the free [I] with HMM K(i, app) method, which is consistent with an underestimation of in vitro inhibition potency in this system. In conclusion, the HHSHP system proved to be a simple, accurate predictor of DDIs for three major P450s and superior to the protein-free approach.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228749     DOI: 10.1124/dmd.111.043158

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance.

Authors:  Barbara Ring; Steven A Wrighton; Michael Mohutsky
Journal:  Methods Mol Biol       Date:  2021

2.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

3.  Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.

Authors:  Jialin Mao; Suzanne Tay; Cyrus S Khojasteh; Yuan Chen; Cornelis E C A Hop; Jane R Kenny
Journal:  Pharm Res       Date:  2016-02-11       Impact factor: 4.200

Review 4.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

5.  Applicability of second-generation upcyte® human hepatocytes for use in CYP inhibition and induction studies.

Authors:  Sarada D Ramachandran; Aurélie Vivarès; Sylvie Klieber; Nicola J Hewitt; Bernhard Muenst; Stefan Heinz; Heike Walles; Joris Braspenning
Journal:  Pharmacol Res Perspect       Date:  2015-08-10

Review 6.  Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.

Authors:  Stephen Fowler; Peter N Morcos; Yumi Cleary; Meret Martin-Facklam; Neil Parrott; Michael Gertz; Li Yu
Journal:  Curr Pharmacol Rep       Date:  2017-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.